Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

  • End date
    Dec 1, 2024
  • participants needed
  • sponsor
    University of Kansas Medical Center
Updated on 4 June 2022
soft tissue sarcoma


This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.


Resection of bony and soft tissue tumors with endoprosthetic reconstruction often presents a significant risk of perioperative blood loss requiring transfusion. Tranexamic acid (TXA) is an antifibrinolytic that is commonly used to reduce blood loss in orthopedic procedures, most often arthroplasty. The aim of this study is to determine in a randomized controlled fashion if there is any difference in perioperative blood loss and blood transfusion rates when TXA is used compared to when it is not used in patients undergoing radical resection of bone and soft tissue sarcomas with endoprosthetic reconstruction.

Condition Musculoskeletal Cancer, Sarcoma,Soft Tissue
Treatment Tranexamic Acid (TXA)
Clinical Study IdentifierNCT04347122
SponsorUniversity of Kansas Medical Center
Last Modified on4 June 2022


Yes No Not Sure

Inclusion Criteria

Patients undergoing wide resection of a malignant bony tumor of the lower extremity with endoprosthetic reconstruction
Patients undergoing a resection of soft tissue sarcoma measuring > 5cm

Exclusion Criteria

Patients undergoing revision endoprosthetic reconstruction
Patients with known coagulopathy
Known history of DVT or embolic disease
Benign tumors
Patients with allergy to TXA
Those refusing blood products
Those concurrently on anti-coagulant therapy
Pregnant and/or nursing women
Vulnerable populations as defined by the KUMC IRB
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note